NCT05628870View on ClinicalTrials.gov

A Trial of HRS-1358 Tablets in Metastatic or Local Advanced Breast Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

February 7, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions
Breast Cancer
Interventions
DRUG

HRS-1358

HRS-1358 or combination with Dalpiciclib Isethionate Tablets will be administered daily orally in continuous dosing over 28-day cycles.

Trial Locations (1)

100021

RECRUITING

Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing

All Listed Sponsors
lead

Shandong Suncadia Medicine Co., Ltd.

INDUSTRY